IBEX 35
11.106,40 +74,10 (+0,67%) Euro Stoxx 50
4.942,64 +35,34 (+0,72%) Dólar/Euro
1,0741 +0,0044 (+0,41%) Petróleo Brent
84,98 -0,26 (-0,31%) Oro
2.338,80 +7,60 (+0,33%) Bitcoin EUR
56.904,69 -2.953,20 (-4,93%)
scPharmaceuticals Inc. (2SX.F)
scPharmaceuticals Inc.
25 Mall Road
Suite 203
Burlington, MA 01803
United States
617 517 0730
https://www.scpharmaceuticals.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 135
Descripción
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de scPharmaceuticals Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.
